Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical’s rights issue amounting SEK 29 million has been oversubscribed

Regulatory information
Hansa Medical’s rights issue has been subscribed at 116 %, of which 88 % has been subscribed through preferential rights. The rights issue provides Hansa Medical with SEK 29 million before issue expenses.

The rights issue comprises 5,794,776 shares. 5,074,287 shares were subscribed for through preferential rights corresponding to 88% of the total amount of issued shares. In addition, 1,647,396 shares have been subscribed to without preferential rights, corresponding to 28% of the rights issue. On June 21, 2011, information will be sent to those subscribers having subscribed for new shares without the support of subscription rights, who have been allotted shares. Statements will only be sent to subscribers that have been allotted shares.

As a result of the rights issue, the number of Hansa Medical shares will increase by 5,794,776 . After the rights issue the share capital amounts to 67,605,720 distributed on 13,521,144 shares. After registration of the increase in share capital at the Swedish Companies Registration Office, the paid subscription shares (“BTAs”) in the rights issue will be converted to new shares. New shares are expected to become subject to trading on NASDAQ OMX First North on July 13, 2011.

Rights issue in brief
Hansa Medical’s AGM decided on May 12, 2011 to issue 5,794,776 new shares at a price of SEK 5 each. At full subscription, the share issue raises SEK 29 million before issue expenses. Shareholders in Hansa Medical AB had preferential rights to the subscription of new shares and four existing shares entitled to subscription of three new shares. The share issue was fully secured by Farstorp Invest AB. The subscription period was from May 26 through June 14, 2011.

The motive for the new share issue is to achieve critical and highly valuable development milestones. Hansa Medical intends to initiate clinical studies of the drug candidate IdeS, to accomplish a registration and launch of the diagnostic method HMD-301, to identify an anti-alpha.11 drug candidate appropriate for clinical development and possibly, bring a new and innovative research finding into development.

Downloads